All Stories

  1. Tenders for the Procurement of Medical Devices: Adapting Cost-Effectiveness Rules to the Requirements of the European Public Procurement Directive
  2. Incremental Cost-Effectiveness Ratio and Net Monetary Benefit
  3. Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women [Corrigendum]
  4. Estimating the 95% confidence interval for survival gain between an experimental anti-cancer treatment and a control
  5. Rituximab biosimilar in rheumatoid arthritis: an enhanced-evidence assessment to evaluate equivalence with the originator based on network meta-analysis
  6. Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women
  7. Pricing of innovative drugs: correlation between incremental cost and survival gain in four countries
  8. Corrigendum to “Anti-platelet treatments in acute coronary syndrome: simplified network meta-analysis” [Int J Cardiol Pages 364–367]
  9. Glutamine in critically ill patients: Trial-sequential analysis
  10. Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods
  11. An Italian perspective
  12. Application of the Gompertz Method for Evaluating Survival Gains in Patients Receiving Cardiac Resynchronization Therapy
  13. Biological Drugs for the Treatment of Moderate-to-Severe Psoriasis by Subcutaneous Route: Determining Statistical Equivalence According to Evidence-Based Methods
  14. Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
  15. Intramyocardial bone marrow-derived cells for ischemic heart disease: Is the benefit clinically relevant?
  16. Outcomes with short-term versus long-term antiplatelet dual therapy after drug-eluting stenting: Quantifying the equivalence margins
  17. Rates of Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A Treated with Plasma-Derived or Recombinant Factor VIII: No Proof of Difference or Proof of No Difference?
  18. Same-Day Discharge After Percutaneous Coronary Intervention
  19. Risk of Myocardial Infarction With Oral Direct Thrombin Inhibitors: Trial Sequential Analysis Based on Two Published Data Sets
  20. Pegylated interferon-α2a versus pegylated interferon-α2b in hepatitis C
  21. Risk of intracranial haemorrhage in patients with atrial fibrillation treated with novel oral anticoagulants: testing the equivalence margins between dabigratran, rivaroxaban and apixaban
  22. Are Newer-Generation Drug-Eluting Stents More Effective in Women than Early-Generation Ones?
  23. Parenteral vs oral iron in patients with inflammatory bowel disease: Quantifying information size by trial sequential analysis
  24. Intra-aortic balloon pump in high-risk percutaneous coronary interventions without cardiogenic shock: Trial sequential analysis of outcomes
  25. Effectiveness of drug-eluting balloons: Quantifying the information size from clinical trials
  26. The need to know crude event rates in meta-analysis
  27. Müllerian Adenosarcoma: A Frequently Misinterpreted Diagnosis
  28. Dabigatran in atrial fibrillation
  29. Off-pump versus on-pump coronary artery bypass grafting: Quantifying information size by trial sequential analysis
  30. Omega-3 polyunsaturated fatty acids for patients at risk of sudden cardiac death and ventricular arrhythmias: Trial sequential analysis
  31. Intracoronary Infusion of Bone-marrow Derived Mononuclear Cells in Acute Myocardial Infarction: Are Outcomes Influenced by the Number of Infused Cells?
  32. ω-3 Fatty Acid Supplements for Secondary Prevention of Cardiovascular Disease: From “No Proof of Effectiveness” to “Proof of No Effectiveness”
  33. Erythropoietin in Patients With Acute Myocardial Infarction: No Proof of Effectiveness or Proof of No Effectiveness?
  34. Erythropoiesis‐stimulating agents in heart failure: no proof of effectiveness or proof of no effectiveness?
  35. Temporal trend of short-term mortality in severely ill patients receiving parenteral glutamine supplementation
  36. Comparing new anticoagulants in atrial fibrillation using the number needed to treat
  37. Viscosupplementation in patients with knee osteoarthritis: temporal trend of benefits assessed by meta-regression
  38. Mechanical Endovascular Therapy in Ischaemic Stroke: Temporal Trend of Outcomes
  39. Acute lymphoblastic leukemia in first complete remission: temporal trend of outcomes in studies comparing allogeneic transplant with autologous transplant or chemotherapy
  40. Association between migraine and cardiovascular mortality: Is there a temporal trend?
  41. New Endovascular Devices for Acute Ischemic Stroke: Summarizing Evidence by Multiple Treatment Comparison Meta-Analysis
  42. Between-Study Variability of Short-term Mortality in Patients With Pararenal Aortic Pathologies Treated With Chimney or Fenestrated Endografts
  43. Treatments for non‐Hodgkin lymphoma in HIV‐positive patients: Quantifying incremental benefit from 1993 to 2004 by metaregression
  44. Using risk difference as opposed to odds-ratio in meta-analysis
  45. Outcomes in Patients With Unprotected Left Main Coronary Disease: Comparison Between Drug-Eluting Stents and Coronary Artery By-Pass Grafting
  46. All-Cause Mortality in Patients With Unprotected Left Main Coronary Disease: Comparison Between Stenting and Coronary Artery Bypass Grafting
  47. New and old anti-thrombotic treatments for patients with atrial fibrillation
  48. Maintenance Chemotherapy in Ovarian Cancer: A Trial-Sequential Analysis
  49. Does network meta-analysis generate any new knowledge?
  50. Meta-Analysis of Observational Studies to Evaluate Immediate Outcomes After Endarterectomy or Stenting for Carotid Artery Stenosis
  51. Temporal Trend of Overall Survival in Patients with Advanced Non-small Cell Lung Cancer Given First-Line Cytotoxic Treatments
  52. Antipsychotic drugs for relapse prevention in schizophrenia
  53. Defining innovations of therapeutic interventions: a position paper by the Italian Society of Hospital Pharmacists
  54. Immediate and late outcome of patients aged 80 years and older undergoing isolated aortic valve replacement: A systematic review and meta-analysis of 48 studies
  55. Interpreting randomised trials evaluating newer agents or interferon in multiple sclerosis
  56. Effect of discounting on estimation of benefits determined by hepatitis C treatment
  57. Nationwide prediction of future expenditure for protease inhibitors in chronic hepatitis C
  58. Treatments for relapsing–remitting multiple sclerosis: summarising current information by network meta-analysis
  59. Anti-platelet treatments in acute coronary syndrome: Simplified network meta-analysis
  60. Definizione di farmaco innovativo: rivisitazione in un contesto di risorse limitate
  61. Treatments for macular degeneration: summarising evidence using network meta-analysis
  62. First-line treatments for hepatitis C
  63. The Role of Bortezomib, Thalidomide and Lenalidomide in the Management of Multiple Myeloma
  64. Results can be summarised in a simple figure
  65. Un’esigenza di chiarezza: differenziare il payback “value-based” da quello non “value-based”
  66. Long-term dual antiplatelet therapy after percutaneous coronary intervention
  67. Relating price determination to disease prevalence
  68. Outcome based schemes are more common than you think
  69. Randomized Study of Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Inappropriate Conclusions
  70. Risk‐sharing approach for managing factor VIIa reimbursement in haemophilia patients with inhibitors
  71. Emerging transcatheter therapies for aortic and mitral disease
  72. Left ventricular assist device as destination therapy: Application of the payment-by-results approach for the device reimbursement
  73. Inappropriate comparison of survival rates at 30 days in transplanted patients previously implanted or not with left ventricular assist devices
  74. Cost Effectiveness of Sunitinib
  75. High‐density polyethylene reinforced with submicron titania particles
  76. Effect of Food on Lapatinib Pharmacokinetics
  77. PPRS is not NICE
  78. Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohnʼs disease patients: A project of the European Collaborative Study Group on Inflammatory Bowel Disease
  79. Heterogeneity in the evaluation of observational studies by Italian ethics committees
  80. Clinical-economic appropriateness of drug treatments: designing a method that combines evidence-based information and cost assessments to construct league tables accounting for the potential number of patients
  81. Factors influencing the length of hospitalisation in intensive care units: a prospective observational study
  82. New Drugs for Rheumatoid Arthritis
  83. Guadagno di sopravvivenza dei nuovi farmaci
  84. Beneficio clinico e prezzo dei farmaci
  85. Prevention of coronary heart disease
  86. Dropout rates with olanzapine or risperidone: a multi-centre observational study
  87. "Polypill" to fight cardiovascular disease: Cost effectiveness of statins for primary prevention of cardiovascular events is questionable
  88. Controvalore economico del farmaco e beneficio clinico: stato dell’arte della metodologia e applicazione di un algoritmo farmacoeconomico
  89. Pharmacotherapy of multiple myeloma: an economic perspective
  90. Clinical Trial Response and Dropout Rates with Olanzapine versus Risperidone
  91. Comparative Effectiveness of Antipsychotic Drugs
  92. Survival of Patients with Recurrent???Malignant Glioma Treated???with Temozolomide
  93. PNP8 ADJUNCTIVE TOPIRAMATE THERAPY IN PATIENTS WITH REFRACTORY SEIZURES:A LIFETIME COST-UTILITY ANALYSIS
  94. Quality of Life and Utility in Patients with Non-Small Cell Lung Cancer
  95. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled
  96. Survival Meta-Analysis of Individual Patient Data and Survival Meta-Analysis of Published (Aggregate) Data
  97. Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol
  98. Biliary stents in neoplastic strictures: plastic versus metal throughout evidence based medicine
  99. A new method for expressing survival and life expectancy in lifetime cost-effectiveness studies that evaluate cancer patients (review).
  100. Cost Effectiveness of Riluzole in Amyotrophic Lateral Sclerosis
  101. PMC3: SURVIVAL GAINS AND DEGREE OF THERAPEUTIC INNOVATION
  102. W7: HANDLING SURVIVAL DATA IN COST-EFFECTIVENESS ANALYSIS
  103. PCA6: COST-EFFECTIVENESS OF GEMCITABINE AS FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED PANCREATIC CANCER
  104. CAN1: COST-EFFECTIVENESS ANALYSIS OF HIGH-DOSE CHEMOTHERAPY WITH HEMATOPOIETIC RESCUE AS PRIMARY TREATMENT FOR METASTATIC BREAST CANCER
  105. CAN2: A NEW METHOD FOR EXPRESSING SURVIVAL AND LIFE EXPECTANCY IN CANCER PATIENTS
  106. Pharmacoeconomic profile of taxanes in advanced ovarian cancer
  107. Maintenance Treatment with Interferon in Multiple Myeloma
  108. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma
  109. Drug Treatments for Maintaining Remission in Crohnʼs Disease
  110. Cost-Effectiveness of Interferon-α as Maintenance Therapy in Chronic Myelogenous Leukemia
  111. Survival curve fitting using the Gompertz function: a methodology for conducting cost-effectiveness analyses on mortality data
  112. Erratum to: Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer
  113. Cost Effectiveness of Adjuvant Intraportal Chemotherapy in Patients with Colorectal Cancer
  114. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma: A lifetime cost-effectiveness analysis
  115. Pharmacoeconomic profile of paclitaxel as a first‐line treatment for patients with advanced ovarian carcinoma: A lifetime cost‐effectiveness analysis
  116. Intermittent negative pressure ventilation in the treatment of hypoxic hypercapnic coma in chronic respiratory insufficiency.
  117. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer
  118. Effectiveness of Immunoglobulins for the Prevention of Systemic Infections
  119. Effectiveness of gabexate mesilate in acute pancreatitis
  120. Cisplatin Pharmacokinetics Using a Five-Day Schedule During Repeated Courses of Chemotherapy in Germ Cell Tumors
  121. EXAFS studies of Fe(III)-phosvitin at high metal to protein ratios
  122. Meta-analysis on the Maintenance of Remission in Crohnʼs Disease
  123. Pharmacokinetics, thrombogenicity and safety of a double-treated prothrombin complex concentrate
  124. Meta-analysis of clinical trials based on censored end-points: simplified theory and implementation of the statistical algorithms on a microcomputer
  125. Calculation Errors in Meta-Analysis
  126. Antibiotics Secretion into Pancreatic Fluid
  127. New Schedule of Administration in the Treatment of Acute Myeloid Leukemia
  128. Clinical Features, Pathogenesis and Management of Drug-Induced Seizures
  129. Bioavailability of Intramuscular Ciclosporin in the Pig
  130. Ofloxacin penetration into bile and pancreatic juice
  131. Clinical Pharmacokinetics of Valproic Acid - 1988
  132. PROGNOSTIC FACTORS IN HODGKIN'S DISEASE
  133. 13-cis-Retinoic Acid Treatment in Patients with Myelodysplastic Syndrome
  134. Clinical Pharmacokinetics of Factor VIII in Patients with Classic Haemophilia
  135. Single‐dose pharmacokinetics of Factor IX evaluated by model‐independent methods
  136. Ciprofloxacin Penetration in Pancreatic Juice
  137. Changes in immunoreactive β-endorphin, methionine-enkephalin and ACTH in bone marrow cells and fluid from leukemic children
  138. HALF-LIFE AND IN-VIVO RECOVERY OF HEATED FACTOR VIII CONCENTRATES
  139. Pharmacokinetics of a new heat-treated concentrate of factor VIII estimated by model-independent methods
  140. A calculator program for clinical application of the Bayesian method of predicting plasma drug levels
  141. Rifampicin concentrations in pancreatic juice
  142. INDIVIDUALIZATION OF FACTOR VIII DOSAGE
  143. A calculator program for least-squares parameter estimation according to the one-compartment kinetic model with zero-order input
  144. COMPARATIVE ANALYSIS OF THE PHARMACOKINETIC TECHNIQUES AVAILABLE FOR INDIVIDUALIZING PHENYTOIN DOSAGE
  145. Clinical studies of pharmacodynamic interactions between antiepileptic drugs and other drugs